DS-1442 / Daiichi Sankyo - LARVOL DELTA

Effects of the CETP inhibitor DS-1442 on reverse cholesterol transport and atherosclerosis (EAS 2013) - Presentation time: 02.06.2013, 09:00-17:00; “DS-1442 treatment elevated HDL-cholesterol at ≥0.1 mg/kg (P< 0.05) and decreased non-HDL-cholesterol at ≥0.3 mg/kg (P< 0.05). Treatment with DS-1442b at 0.1 mg/kg or more reduced the atherosclerotic lesion area by similar extent to that in LDLR-/- mice (P< 0.05).”

Preclinical • Atherosclerosis • Dyslipidemia